Literature DB >> 31610176

Insights into Fibroblast Plasticity: Cellular Communication Network 2 Is Required for Activation of Cancer-Associated Fibroblasts in a Murine Model of Melanoma.

Matthew Tsang1, Katherine Quesnel2, Krista Vincent3, James Hutchenreuther1, Lynne-Marie Postovit4, Andrew Leask5.   

Abstract

Tumor stroma resembles a fibrotic microenvironment, being characterized by the presence of myofibroblast-like cancer-associated fibroblasts (CAFs). In wild-type mice injected with melanoma cells, we show that the stem cell transcription factor Sox2 is expressed by tumor cells and induced in CAFs derived from synthetic fibroblasts. These fibroblasts were labeled postnatally with green fluorescent protein using mice expressing a tamoxifen-dependent Cre recombinase under the control of a fibroblast-specific promoter/enhancer. Conversely, fibroblast activation was impaired in mice with a fibroblast-specific deletion of cellular communication network 2 (Ccn2), associated with reduced expression of α-smooth muscle actin and Sox2. Multipotent Sox2-expressing skin-derived precursor (SKP) spheroids were cultured from murine back skin. Using lineage tracing and flow cytometry, approximately 40% of SKPs were found to be derived from type I collagen-lineage cells and acquired multipotency in culture. Inhibition of mechanotransduction pathways prevented myofibroblast differentiation of SKPs and expression of Ccn2. In SKPs deleted for Ccn2, differentiation into a myofibroblast, but not an adipocyte or neuronal phenotype, was also impaired. In human melanoma, CCN2 expression was associated with a profibrotic integrin alpha (ITGA) 11-expressing subset of CAFs that negatively associated with survival. These results suggest that synthetic dermal fibroblasts are plastic, and that CCN2 is required for the differentiation of dermal progenitor cells into a myofibroblast/CAF phenotype and is, therefore, a therapeutic target in melanoma.
Copyright © 2020 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31610176     DOI: 10.1016/j.ajpath.2019.09.006

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  8 in total

1.  Report on the 10th international workshop on the CCN family of genes October 21-24, 2019, Niagara Falls, Canada.

Authors:  Andrew Leask; Bernard Perbal
Journal:  J Cell Commun Signal       Date:  2020-08-26       Impact factor: 5.782

Review 2.  Conjunction junction, what's the function? CCN proteins as targets in fibrosis and cancers.

Authors:  Andrew Leask
Journal:  Am J Physiol Cell Physiol       Date:  2020-03-04       Impact factor: 4.249

Review 3.  The CCN axis in cancer development and progression.

Authors:  Herman Yeger; Bernard Perbal
Journal:  J Cell Commun Signal       Date:  2021-04-20       Impact factor: 5.782

Review 4.  CCN2 (Cellular Communication Network factor 2) in the bone marrow microenvironment, normal and malignant hematopoiesis.

Authors:  Roos J Leguit; Reinier A P Raymakers; Konnie M Hebeda; Roel Goldschmeding
Journal:  J Cell Commun Signal       Date:  2021-01-11       Impact factor: 5.782

5.  Excessive activation of IL-33/ST2 in cancer-associated fibroblasts promotes invasion and metastasis in ovarian cancer.

Authors:  Caixia Feng; Li Kou; Panyue Yin; Yuan Jing
Journal:  Oncol Lett       Date:  2022-03-17       Impact factor: 2.967

Review 6.  Role of Peritoneal Mesothelial Cells in the Progression of Peritoneal Metastases.

Authors:  Junliang Li; Tiankang Guo
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

7.  Slow train coming: an anti-CCN2 strategy reverses a model of chronic overuse muscle fibrosis.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2020-09       Impact factor: 5.782

Review 8.  Acidic and Hypoxic Microenvironment in Melanoma: Impact of Tumour Exosomes on Disease Progression.

Authors:  Zaira Boussadia; Adriana Rosa Gambardella; Fabrizio Mattei; Isabella Parolini
Journal:  Cells       Date:  2021-11-25       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.